Correction to: BMC Urol (2020) 20:139 https://doi.org/10.1186/s12894-020-00689-0
In the original publication of this article [1] there were several errors in Table 1 related to the values for Disease status (nmCRPC and mCSPC).
In this correction article the correct and incorrect values are shown.
Anzeige
Table 1 The correct and incorrect values
Incorrect | Correct | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Disease status, n | Disease status, n | ||||||||
nmCRPC | 55 | – | – | 55 | nmCRPC | 34 | – | – | 34 |
mCSPC | – | 51 | – | 51 | mCSPC | – | 28 | – | 28 |
Furthermore, the Time-to-event analyses section has several errors with the decimal values/rounding of numbers, the incorrect and correct information is shown below
Incorrect | Correct |
|---|---|
66 days | 66.0 days |
45 days | 45.0 days |
52 days | 52.0 days |
38 days | 38.0 days |
82 days | 82.0 days |
In the global population of the SPARTAN study, skin rash of any grade resolved for 81% of the patients within 59.5 days, while the median time to resolution of skin rash of any grade in the TITAN study was 100 days (Supplementary Table 2) | In the global population of the SPARTAN study, skin rash of any grade resolved for 80.6% of the patients within 59.5 days, while the median time to resolution of skin rash of any grade in the TITAN study was 100.0 days (Supplementary Table 2) |
100 days | 100.0 days |
35 days | 35.0 days |
37 days | 37.0 days |
66 days | 66.0 days |
Anzeige
Further errors were detected, specifically under the section Management of Rash. This Correction article shows the incorrect and correct sentences. It was highlighted that some of the values on Table 3 were also incorrect. This Correction article shows the correct Table 3. The original article has been updated.
Incorrect:
Oral antihistamine was the most common (25/35 [71.4%]), followed by systemic and topical corticosteroids (18/35 [51.4%] and 15/35 [42.9%], respectively) (Table 3).
Correct:
Topical corticosteroid was the most common (27/35 [77.1%]), followed by oral antihistamine and systemic corticosteroid (18/35 [51.4%] and 3/35 [8.6%], respectively) (Table 3).
Table 3
Rash management Target population: Safety
SPARTAN | TITAN | PCR1008 | Total | |
|---|---|---|---|---|
Number of safety analysis set | 34 | 28 | 6 | 68 |
Rash | 19 (55.88) | 14 (50.00) | 2 (33.33) | 35 (51.47) |
Patients who received supportive care for rash | ||||
Oral antihistamine | 11 (57.89) | 6 (42.86) | 1 (50.00)
| 18 (51.43)
|
Systemic corticosteroid | 0 (0.00) | 3 (21.43)
| 0 (0.00)
| 3 (8.57)
|
Topical corticosteroid | 13 (68.42) | 13 (92.86)
| 1 (50.00)
| 27 (77.14)
|
Drug interruption | 11 (57.89) | 6 (42.86)
| 1 (50.00)
| 18 (51.43)
|
Dose reduction | 4 (21.05) | 3 (21.43)
| 0 (0.00)
| 7 (20.00)
|
Drug discontinuation | 3 (15.79) | 2 (14.29)
| 0 (0.00)
| 5 (14.29)
|
Other | 2 (10.53) | 1 (7.14)
| 0 (0.00)
| 3 (8.57)
|
In the Discussion section:
Incorrect:
This could be attributed to the more frequent use of oral antihistamines (71.4%) and systemic corticosteroids (51.4%) as supportive medication among Japanese patients when compared with patients in the global studies (combined data from SPARTAN and TITAN: antihistamines, 36.5%; systemic corticosteroids, 18.5%).
Anzeige
Correct:
This could be attributed to the more frequent use of topical corticosteroids (77.1%) and oral antihistamines (51.4%) as supportive medication among Japanese patients when compared with patients in the global studies (combined data from SPARTAN and TITAN: topical corticosteroids, 37.8%; antihistamines, 36.3%.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.